Patents by Inventor Marit Kristiansen

Marit Kristiansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Urea glucokinase activators
    Patent number: 8586614
    Abstract: The invention provides a compound of general formula (I) wherein the substituents are defined further in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: November 19, 2013
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Anthony Murray, Per Vedso, Marit Kristiansen, Lone Jeppesen
  • Heteroaryl-ureas and their use as glucokinase activators
    Patent number: 8263634
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: September 11, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswarak Santhosh
  • Heteroaromatic glucokinase activators
    Patent number: 8148412
    Abstract: The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, of Formula (I) wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; pharmaceutical compositions comprising the same; and, methods of using the same. The propionamides are glucokinase activators for the treatment of type II diabetes.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: April 3, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Lone Jeppesen, Marit Kristiansen
  • Dicycloalkylcarbamoyl ureas as glucokinase activators
    Patent number: 7999114
    Abstract: This invention relates to dicycloalkylcarbamoyl ureas of formula (I), which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: August 16, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Per Vedso, Lone Jeppesen, Marit Kristiansen
  • HETEROAROMATIC GLUCOKINASE ACTIVATORS
    Publication number: 20110130402
    Abstract: The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; pharmaceutical compositions comprising the same; and, methods of using the same. The propionamides are glucokinase activators which increase insulin secretion for the treatment of type II diabetes.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 2, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Lone Jeppesen, Marit Kristiansen
  • Urea Glucokinase Activators
    Publication number: 20110077234
    Abstract: The invention provides a compound of general formula (I) wherein the substituents are defined further in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.
    Type: Application
    Filed: December 7, 2010
    Publication date: March 31, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Anthony Murray, Per Vedso, Marit Kristiansen, Lone Jeppesen
  • HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS
    Publication number: 20110060019
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: November 9, 2010
    Publication date: March 10, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswarak Santhosh
  • Ureido-thiazole glucokinase activators
    Patent number: 7884210
    Abstract: The invention provides a compound of general formula (I) wherein the compounds are of the class ureido-thiazole glucokinase activators, useful for the treatment of various diseases, for example, type 2 diabetes.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: February 8, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Anthony Murray, Per Vedso, Marit Kristiansen, Lone Jeppesen
  • Heteroaryl-ureas and their use as glucokinase activators
    Patent number: 7872139
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: August 8, 2008
    Date of Patent: January 18, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaram Santhosh
  • Heteroaryl-ureas and their use as glucokinase activators
    Patent number: 7851636
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: December 14, 2010
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaram Santhosh
  • Heteroaryl-Ureas and Their Use as Glucokinase Activators
    Publication number: 20100204288
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: April 9, 2010
    Publication date: August 12, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaran Santhosh
  • Heteroaryl-ureas and their use as glucokinase activators
    Patent number: 7598391
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: October 6, 2009
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsø, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaran Santhosh
  • Dicycloalkyl urea glucokinase activators
    Patent number: 7582769
    Abstract: Dicycloalkyl urea glucokinase activators compounds are glucokinase inhibitors useful for the treatment of diabetes.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: September 1, 2009
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Per Vedso, Marit Kristiansen, Lone Jeppesen
  • Heteroaryl-Ureas and Their Use as Glucokinase Activators
    Publication number: 20090216013
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: August 8, 2008
    Publication date: August 27, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedso, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce-Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswara Santhosh
  • Dicycloalkyl Urea Glucokinase Activators
    Publication number: 20090118501
    Abstract: Dicycloalkyl urea glucokinase activators compounds are glucokinase inhibitors useful for the treatment of diabetes.
    Type: Application
    Filed: July 7, 2006
    Publication date: May 7, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Per Vedso, Marit Kristiansen, Lone Jeppesen
  • Urea Glucokinase Activators
    Publication number: 20090105482
    Abstract: The invention provides a compound of general formula (I) wherein the substituents are defined further in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.
    Type: Application
    Filed: July 14, 2006
    Publication date: April 23, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Anthony Murray, Per Vedso, Marit Kristiansen, Lone Jeppesen
  • Dicycloalkylcarbamoyl Ureas As Glucokinase Activators
    Publication number: 20080319028
    Abstract: This invention relates to dicycloalkylcarbamoyl ureas of formula (I), which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Application
    Filed: July 7, 2006
    Publication date: December 25, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Per Vedso, Lone Jeppesen, Marit Kristiansen
  • Heteroaromatic Glucokinase Activators
    Publication number: 20080139562
    Abstract: The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, of Formula (I) wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; pharmaceutical compositions comprising the same; and, methods of using the same. The propionamides are glucokinase activators for the treatment of type II diabetes.
    Type: Application
    Filed: December 5, 2005
    Publication date: June 12, 2008
    Applicant: Novo Nordisk A/S
    Inventors: Lone Jeppesen, Marit Kristiansen
  • Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV
    Patent number: 7235538
    Abstract: The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV, which are of formula I wherein each n is one or two independently and R1, R2, R3, R6, R7, R9, and R10 are defined herein. The present invention also relates to pharmaceutical compositions comprising the compounds of formula I and the use of the compounds for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type-2 diabetes and obesity.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: June 26, 2007
    Assignee: Novo Nordisk A/S
    Inventors: Anders Bendtz Kanstrup, Lise Brown Christiansen, Jane Marie Lundbeck, Christian K. Sams, Marit Kristiansen
  • Heteroaryl-ureas and their use as glucokinase activators
    Patent number: RE45183
    Abstract: This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: October 7, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Murray, Jesper Lau, Lone Jeppesen, Per Vedsoe, Michael Ankersen, Jane Marie Lundbeck, Marit Kristiansen, Maria Carmen Valcarce Lopez, Dharma Rao Polisetti, Govindan Subramanian, Robert Carl Andrews, Daniel P. Christen, Jeremy T. Cooper, Kalpathy Chidambareswaran Santhosh